A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHN Who Have Failed Platinum Based Therapy
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2018
At a glance
- Drugs Cabozantinib (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 22 Sep 2018 Planned End Date changed from 31 Jul 2021 to 30 Sep 2020.
- 22 Sep 2018 Planned primary completion date changed from 31 Jul 2021 to 30 Sep 2020.
- 22 Sep 2018 Status changed from not yet recruiting to recruiting.